According to Zacks, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. “
IPCI has been the topic of a number of other research reports. Brean Capital reiterated a buy rating and set a $8.00 price target on shares of Intellipharmaceutics International in a report on Tuesday, July 5th. Maxim Group set a $6.00 price target on Intellipharmaceutics International and gave the company a buy rating in a report on Thursday, October 6th.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.75 on Thursday. The firm’s 50-day moving average price is $2.12 and its 200 day moving average price is $1.87. The stock’s market capitalization is $79.05 million. Intellipharmaceutics International has a 12-month low of $1.41 and a 12-month high of $3.33.
Intellipharmaceutics International (NASDAQ:IPCI) last issued its quarterly earnings results on Friday, October 14th. The company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 371.11%. Analysts predict that Intellipharmaceutics International will post ($0.28) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC bought a new position in shares of Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International as of its most recent filing with the SEC. 1.34% of the stock is currently owned by institutional investors.
About Intellipharmaceutics International
IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.